GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Notes Receivable

ZYUS Life Sciences (TSXV:ZYUS) Notes Receivable : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Notes Receivable?

ZYUS Life Sciences's Notes Receivable for the quarter that ended in Mar. 2024 was C$0.00 Mil.


ZYUS Life Sciences Notes Receivable Historical Data

The historical data trend for ZYUS Life Sciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences Notes Receivable Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
- - -

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ZYUS Life Sciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ZYUS Life Sciences Notes Receivable Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines